BDO has recently provided financial, tax and commercial due diligence to Bionical Ltd (the integrated outsourced specialist to the pharmaceutical, biotechnology and public health industry) on the acquisition of Emas Pharma ('Emas'), a global Clinical Research Organisation.
Emas, provides pharmaceutical development and clinical research services to biotech, medical device and specialised pharmaceutical companies worldwide. It is Bionical’s third strategic acquisition in little over a year, following the successful acquisitions in 2015 of UK based North 51 and US based McCallan Healthcare. These earlier acquisitions brought public health, digital, educational and further commercial services to the rapidly-strengthening Bionical brand, ahead of the current EMAS acquisition, which unifies and completes Bionical’s patient-centric service portfolio.
The acquisition of Emas Pharma satisfies a number of our key strategic goals and throughout the transaction, the BDO team were proactive, flexible and showed great commitment to deliver in full. They offered valuable financial and commercial advice and their sector insight helped to focus in on the critical issues. The reports were of an excellent standard and we would be happy to recommend their services.
Graham Mcintosh - Managing Director, Bionical Ltd